Skip to main content
CRDF
NASDAQ Life Sciences

FDA Grants Fast Track to Onvansertib in First-Line RAS-Mutated Colorectal Cancer

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.833
Mkt Cap
$56.487M
52W Low
$0.711
52W High
$3.31
52W Position info
17% above low
Off High info
75% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

CRDF sits 17% above its 52-week low of $0.711 on light trading volume (0.3× avg).

Summary

The FDA granted Fast Track designation to onvansertib plus FOLFIRI/bevacizumab for first-line KRAS- or NRAS-mutated metastatic colorectal cancer, a setting with no specifically approved therapy. The designation rests on the randomized Phase 2 CRDF-004 data: the proposed 30 mg Phase 3 regimen posted a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone, and median progression-free survival in the 30 mg arm had not been reached as of September 28, 2026, versus roughly 11 months in the standard-of-care arms. Fast Track opens more frequent FDA interaction and eligibility for rolling review and, if criteria are met, Accelerated Approval and Priority Review — meaningful for a company whose Q3 10-Q showed $33.8 million in cash and investments funding operations only to the end of Q3 2027 with going-concern doubt. It follows October's orphan designation in CMML and a November orphan designation in small cell lung cancer, building a regulatory momentum narrative around the lead asset. The next concrete step is advancing onvansertib into the planned registrational trial in first-line RAS-mutated mCRC.

At the time of this announcement, CRDF was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.5M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.8677 info
Change: +$0.1401 (+19%) info
Market Cap: $56.487M info
CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.8677 info
Change: +$0.1401 (+19%) info
Market Cap: $56.487M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.8677 info
Change: +$0.0982 (+13%) info
Market Cap: $56.487M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.8677 info
Change: -$0.0311 (-3%) info
Market Cap: $56.487M info
CRDF
Oct 21, 2026, 6:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.8677 info
Change: -$0.0823 (-9%) info
Market Cap: $56.487M info